GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » EV-to-EBITDA

ReNeuron Group (LSE:RENE) EV-to-EBITDA : 0.48 (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ReNeuron Group's enterprise value is £-2.80 Mil. ReNeuron Group's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was £-5.79 Mil. Therefore, ReNeuron Group's EV-to-EBITDA for today is 0.48.

The historical rank and industry rank for ReNeuron Group's EV-to-EBITDA or its related term are showing as below:

LSE:RENE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.25   Med: -1.15   Max: 1.31
Current: 0.48

During the past 13 years, the highest EV-to-EBITDA of ReNeuron Group was 1.31. The lowest was -9.25. And the median was -1.15.

LSE:RENE's EV-to-EBITDA is ranked better than
79.45% of 472 companies
in the Biotechnology industry
Industry Median: 9.1 vs LSE:RENE: 0.48

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), ReNeuron Group's stock price is £0.03375. ReNeuron Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.089. Therefore, ReNeuron Group's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


ReNeuron Group EV-to-EBITDA Historical Data

The historical data trend for ReNeuron Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group EV-to-EBITDA Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.42 -1.47 -3.53 -0.32 0.24

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.32 - 0.24 -

Competitive Comparison of ReNeuron Group's EV-to-EBITDA

For the Biotechnology subindustry, ReNeuron Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's EV-to-EBITDA falls into.



ReNeuron Group EV-to-EBITDA Calculation

ReNeuron Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-2.800/-5.785
=0.48

ReNeuron Group's current Enterprise Value is £-2.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ReNeuron Group's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was £-5.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group  (LSE:RENE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ReNeuron Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.03375/-0.089
=At Loss

ReNeuron Group's share price for today is £0.03375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ReNeuron Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.089.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


ReNeuron Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.